ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Company Overview - ImageneBio, Inc. is a clinical-stage biotechnology company focused on developing treatments for immunological/autoimmune and inflammatory diseases [3] - The company's lead asset, IMG-007, is a nondepleting anti-OX40 monoclonal antibody that has completed clinical trials for atopic dermatitis and alopecia areata [3] - Currently, ImageneBio is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis [3] Executive Compensation - On July 28, 2025, ImageneBio granted equity awards to Dr. Kristin Yarema, the newly appointed CEO, which included inducement stock options for 436,080 shares and inducement restricted stock units (RSUs) for 153,505 shares [1] - The inducement stock options have an exercise price of $16.37 per share, a ten-year term, and vest over four years with specific vesting schedules [2] - The RSUs will also vest over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting quarterly [2]